Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival rate of 95 percent when patients received fewer weeks of neoadjuvant total androgen suppression. Read more here.